| Website | protoxtherapeutic... |
| Category | BioTech |
| Phone | 604.688.0199 |
| Employees |
| TOTAL | $35M |
| VENTURE FUNDING TOTAL | $35M |
| Venture Round, 9/10 Warburg Pincus | $35M |
Protox Therapeutics Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel receptor targeted therapeutic fusion proteins. The company develops its product based on its PORxin and INxin technology platforms. Its product candidates under clinical development include PRX302, a lead candidate from the PORxin platform, which is under a Phase IIa clinical trial for the treatment of localized and recurrent prostate cancer, as well as under a double-blinded placebo-controlled clinical trial for the treatment of benign prostatic hyperplasia; and PRX321, a lead candidate derived from INxin platform that has completed a Phase II clinical trial for the treatment of primary brain cancer and a Phase I clinical trial for renal cell and non-small cell lung cancers. The company also focuses on HUMxin technology platform, a program to develop chimeric and fully humanized fusion proteins based upon the Bcl-2 family of proteins. It has a collaborative research and clinical development agreement with BrainLAB AG for use of the BrainLAB proprietary drug delivery software iPlan Flow to plan treatments and catheter placement for delivery and distribution of PRX321. The company was founded in 2002 and is headquartered in Vancouver, Canada.
